Daiichi Sankyo Limited (DSNKY)
| Bid | 23.21 |
| Market Cap | 43.48B |
| Revenue (ttm) | 1,796B |
| Net Income (ttm) | 245.77B |
| EPS (ttm) | 0.9 |
| PE Ratio (ttm) | 25.84 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 23.27 |
| Volume | 18,275 |
| Avg. Volume (20D) | 301,317.3 |
| Open | 23.02 |
| Previous Close | 22.85 |
| Day's Range | 22.89 - 23.33 |
| 52-Week Range | 20.92 - 42.48 |
| Beta | 0.33 |
About DSNKY
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders;...
2 months ago · seekingalpha.com
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call TranscriptDaiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Koji Ogawa -...
2 months ago · businesswire.com
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive OfficerTOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. M...